Tamada Tsutomu, Takeuchi Mitsuru, Watanabe Hiroyuki, Higaki Atsushi, Moriya Kazunori, Kanki Akihiko, Fukukura Yoshihiko, Yamamoto Akira
Department of Radiology, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan.
Department of Radiology, Radiolonet Tokai, Nagoya, Japan.
Discov Oncol. 2024 Dec 18;15(1):770. doi: 10.1007/s12672-024-01668-9.
To investigate the utility of qualitative and semi-quantitative evaluation of DCE-MRI for detecting clinically significant prostate cancer (csPC).
This retrospective study analyzed 307 lesions in 231 patients who underwent 3.0T MRI. Experienced radiologists assessed PI-RADS v 2.1 assessment category, qualitative contrast enhancement (QCE), contrast enhancement pattern (CEP: type 1, 2, 3), tumor contrast ratio, and tumor size of PC lesions in consensus. Mean and 0-10th-percentile ADC value of the lesion (ADC and ADC) were calculated. Specimens obtained from MRI-ultrasound fusion-guided prostate biopsy were used as the pathological reference standard.
In assessment of tumor aggressiveness, PI-RADS assessment category, QCE, tumor size, and ratio of CEP 2 + 3 were significantly higher in PC with Gleason score (GS) ≥ 3 + 4 (n = 256) than in PC with GS = 6 (n = 51) (P ≤ 0.001). Tumor ADC and tumor ADC were comparable between PC with GS ≥ 3 + 4 and PC with GS = 6 (P = 0.164 to 0.504). Regarding diagnostic performance of csPC in 45 PI-RADS 3 transition zone lesions, only ratio of CEP 2 + 3 was significantly higher in PC with GS ≥ 3 + 4 (n = 31) than in PC with GS = 6 (n = 14) (P = 0.008).
Qualitative DCE-MRI indices may contribute to PC aggressiveness and improve detection of csPC in PI-RADS assessment category 3 lesions.
探讨动态对比增强磁共振成像(DCE-MRI)定性和半定量评估在检测临床显著性前列腺癌(csPC)中的应用价值。
本回顾性研究分析了231例接受3.0T磁共振成像检查患者的307个病灶。经验丰富的放射科医生共同评估PI-RADS v 2.1评估类别、定性对比增强(QCE)、对比增强模式(CEP:1型、2型、3型)、肿瘤对比率和前列腺癌病灶的肿瘤大小。计算病灶的平均表观扩散系数(ADC)值和第0至第10百分位数ADC值(ADC₀₋₁₀)。将磁共振成像-超声融合引导下前列腺穿刺活检获取的标本用作病理参考标准。
在评估肿瘤侵袭性时,Gleason评分(GS)≥3+4的前列腺癌(n=256)的PI-RADS评估类别、QCE、肿瘤大小和CEP 2+3比例显著高于GS=6的前列腺癌(n=51)(P≤0.001)。GS≥3+4的前列腺癌与GS=6的前列腺癌之间的肿瘤ADC值和肿瘤ADC₀₋₁₀值相当(P=0.164至0.504)。在45个PI-RADS 3类移行带病灶中,关于csPC的诊断性能,只有GS≥3+4的前列腺癌(n=31)的CEP 2+3比例显著高于GS=6的前列腺癌(n=14)(P=0.008)。
DCE-MRI定性指标可能有助于评估前列腺癌的侵袭性,并提高PI-RADS评估类别3类病灶中csPC的检出率。